Jagsonpal Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.75×	0.75×	0.79×	0.75×	0.77×
	1.15×	1.18×	1.63×	1.40×	1.06×
	17.6%	16.9%	16.0%	10.3%	13.9%
	0.97×	0.97×	1.08×	1.01×	1.30×
	1.21×	1.15×	1.16×	1.16×	1.23×
	17.8%	16.7%	25.8%	12.6%	18.0%
	16.7%	16.7%	25.9%	13.0%	18.4%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JAGSNPHARM₹221.94

Jagsonpal Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersAMRUTANJAN NGLFINE SYNCOMF HESTERBIO SIGACHI LINCOLN WINDLASMcap ₹1,486 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.77	0.75	0.79	0.75	0.75
Interest Burden (Pretax/EBIT) ×	1.06	1.40	1.63	1.18	1.15
EBIT Margin %	13.92	10.26	15.98	16.93	17.59
Asset Turnover ×	1.30	1.01	1.08	0.97	0.97
Financial Leverage (Assets/Equity) ×	1.23	1.16	1.16	1.15	1.21
ROE (5-step product, year-end total equity) %	18.01	12.59	25.80	16.68	17.78
ROE (owners' profit / average owners' equity) %	18.44	12.97	25.91	16.69	16.69

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.